Tumor necrosis factor inhibitors for inflammatory bowel disease.

n engl j med 369;8 nejm.org august 22, 2013 754 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors’ clinical recommendations. John A. Jarcho, M.D., Editor